Price Alert

TNF Pharmaceuticals Inc. (TNFA)

NASDAQ: TNFA · Real-Time Price · USD

3.71

-0.09 (-2.37%)

At close: Sep 03, 2025, 10:12 AM

-2.37% (1D)

Bid	3.33
Market Cap	525.52K
Revenue (ttm)	n/a
Net Income (ttm)	-23.36M
EPS (ttm)	-202
PE Ratio (ttm)	-0.02
Forward PE	n/a
Analyst	n/a

Ask	3.72
Volume	374,920
Avg. Volume (20D)	548,972
Open	3.84
Previous Close	3.80
Day's Range	3.59 - 3.84
52-Week Range	3.52 - 195.00
Beta	2.32

About TNFA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TNFA

Website n/a

Full Company Profile

Why Price Moved

5 days ago

-31.56%

TNF Pharmaceuticals shares are trading lower after... Unlock content with Pro Subscription

7 months ago

-9.4%

TNF Pharmaceuticals shares are trading higher after the company announced that it initiated the first in a series of studies to evaluate the impact of isomyosamine.

News

18 hours ago · businesswire.com

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that it has increased its stake in TNF Pharmaceuticals (Nasdaq: TNFA, “TNF”) by an a...

19 hours ago · businesswire.com

TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications

NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced that it has entered into a licensing agreement for an innovative processing accel...

2 weeks ago · businesswire.com

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmun...

2 months ago · businesswire.com

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease